Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $36.47 USD
Change Today 0.00 / 0.00%
Volume 355.0
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

morphosys ag-sponsored adr (MPSYY) Snapshot

Open
$36.47
Previous Close
$36.47
Day High
$36.47
Day Low
$36.47
52 Week High
12/11/14 - $53.89
52 Week Low
03/26/15 - $30.51
Market Cap
1.9B
Average Volume 10 Days
452.8
EPS TTM
--
Shares Outstanding
52.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MORPHOSYS AG-SPONSORED ADR (MPSYY)

Related News

No related news articles were found.

morphosys ag-sponsored adr (MPSYY) Related Businessweek News

No Related Businessweek News Found

morphosys ag-sponsored adr (MPSYY) Details

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies for therapeutic applications. The company, together with its partners, develops a therapeutic pipeline of approximately 80 human antibody drug candidates for the treatment of musculoskeletal diseases, Alzheimer‘s disease, and rheumatoid arthritis. It operates therapeutic development programs for drug candidates in cooperation with various biotechnology and pharmaceutical companies, as well as focuses on the development of proprietary therapeutic antibodies in the area of inflammatory diseases and oncology. The company’s proprietary product candidates include MOR103, an antibody that is in phase Ib trial for multiple sclerosis; MOR202, a therapeutic antibody that is in phase I/II trial for the treatment of multiple myeloma; and MOR208, which is in phase II clinical trials for patients suffering from diffuse large B-cell lymphoma. MorphoSys AG has strategic alliances with Novartis AG for the discovery and development of biopharmaceuticals; and Celgene Corporation for the co-development of the cancer program MOR202. The company was founded in 1992 and is headquartered in Martinsried, Germany.

329 Employees
Last Reported Date: 02/18/15
Founded in 1992

morphosys ag-sponsored adr (MPSYY) Top Compensated Officers

Chairman of Management Board and Chief Execut...
Total Annual Compensation: €751.2K
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €509.6K
Chief Development Officer and Member of Manag...
Total Annual Compensation: €504.5K
Chief Scientific Officer and Member of Manage...
Total Annual Compensation: €499.5K
Compensation as of Fiscal Year 2014.

morphosys ag-sponsored adr (MPSYY) Key Developments

Morphosys AG Presents at Kempen Healthcare and Life Sciences Conference - New York, Apr-16-2015

Morphosys AG Presents at Kempen Healthcare and Life Sciences Conference - New York, Apr-16-2015 . Venue: New York, New York, United States. Speakers: Claudia Gutjahr-Löser, Head of Corporate Communications & Investor Relations, Simon E. Moroney, Chairman of Management Board and Chief Executive Officer.

Morphosys Nominates Three New Candidates for Supervisory Board

Morphosys AG's Supervisory Board nominated Ms. Wendy Johnson, Mr. Klaus Kuehn and Dr. Frank Morich as candidates to be elected as new members at the Company's AGM 2015. Ms. Johnson, Mr. Kahn and Dr. Morich will replace Dr. Walter Blattler, Dr. Daniel Camus and Dr. Geoffrey Vernon. Dr. Vernon has been a member of MorphoSys AG's Supervisory Board since 1999, while Dr. Camus and Dr. Blattler joined in 2002 and 2007, respectively. Ms. Wendy Johnson currently serves as Managing Director of Gemini Advisors and Interim Chief Operating Officer and Member of the Board of Directors of AmpliPhi BioSciences. Mr. Klaus Kuehn, former Chief Financial Officer of Bayer AG, has more than 30 years of experience in executive positions, primarily in the chemical and pharmaceutical industry with a focus on finance and accounting. Before his appointment as CFO, he served as Head of Finance at Bayer AG and oversaw the spin-off and subsequent IPO of the group's former Agfa division. Dr. Frank Morich, M.D., Ph.D. was most recently Chief Commercial Officer and Member of the Board of Directors of Takeda Pharmaceutical Company Ltd., Tokyo, Japan, as well as Chief Executive Officer of Takeda Pharmaceutical International GmbH.

Morphosys AG Proposes Amendments to the Articles of Association

Morphosys AG to propose amendments to the Articles of Association at the annual general meeting to be held on May 8, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MPSYY:US $36.47 USD 0.00

MPSYY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €9.89 EUR +0.035
Genmab A/S kr529.00 DKK +15.00
ImmunoGen Inc $8.39 USD +0.12
Intrexon Corp $39.93 USD +1.10
XOMA Corp $3.26 USD +0.26
View Industry Companies
 

Industry Analysis

MPSYY

Industry Average

Valuation MPSYY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 24.2x
Price/Book 4.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 19.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MORPHOSYS AG-SPONSORED ADR, please visit www.morphosys.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.